AI drug discovery
The company will use the funds to grow its drug-discovery pipeline and clinical AI stack.
The company will use the funds to bring its AI-enabled offerings into clinical development and advance its platform and portfolio.
The round brings the company's total raise to $93 million.
DenovAI will create an AI-powered platform to discover potential antibodies from scratch, then suggest which ones can be used as effective drugs.
Also, Lunit signed multiple contracts this week to deliver its AI imaging software in Hong Kong, Mongolia, and Brazil.
Also, Edenlux is now providing AI-generated eye health reports in its mobile app.
Also, Syntekabio has launched its cloud service platform for AI drug discovery.
Also, scientists from the University of South Australia have developed tiny fibre sensors for remote patient monitoring.
Also, Standigm has partnered with Merck Korea for AI drug discovery research.
They aim to bring down the period and costs for new drug development.